About
Investor & Media Contact:
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source:
Source:
2022 GlobeNewswire, Inc., source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | -2.60% | -15.25% | -52.83% |
06-04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
05-15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
About
Investor & Media Contact:
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source:
Source:
2022 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-52.83% | 12.5M | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |